![Aclasta Aclasta](/bd-en/sites/novartis_bd/files/styles/crop_freeform/public/2022-09/aclasta_0.jpg.webp?itok=ZSjftH0z)
Product Information
- Treatment of postmenopausal osteoporosis
- Prevention of clinical fractures after a hip fracture
- Treatment of osteoporosis in men
- Treatment and prevention of glucocorticoid-induced osteoporosis
- Prevention of postmenopausal osteoporosis
- Treatment of Paget’s disease of bone
Active Ingredients - Zoledronic Acid 5mg
Product Division - Novartis Pharmaceuticals
Subcategory - Bisphosphonate